Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 223

1.

Correction: Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts.

Yang L, Forker L, Irlam JJ, Pillay N, Choudhury A, West CML.

Oncotarget. 2019 Mar 8;10(20):2007. doi: 10.18632/oncotarget.26783. eCollection 2019 Mar 8.

2.

Correction: The role of indoxyl sulfate in renal anemia in patients with chronic kidney disease.

Wu CJ, Chen CY, Lai TS, Wu PC, Chuang CK, Sun FJ, Liu HL, Chen HH, Yeh HI, Lin CS, Lin CJ.

Oncotarget. 2019 Mar 8;10(20):2006. doi: 10.18632/oncotarget.26782. eCollection 2019 Mar 8.

3.

A global immune gene expression signature for human cancers.

Liu Y.

Oncotarget. 2019 Mar 8;10(20):1993-2005. doi: 10.18632/oncotarget.26773. eCollection 2019 Mar 8.

4.

Specific allelic variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients.

Bauer M, Kantelhardt EJ, Stiewe T, Nist A, Mernberger M, Politt K, Hanf V, Lantzsch T, Uleer C, Peschel S, John J, Buchmann J, Weigert E, Bürrig KF, Wickenhauser C, Thomssen C, Bartel F, Vetter M.

Oncotarget. 2019 Mar 8;10(20):1975-1992. doi: 10.18632/oncotarget.26768. eCollection 2019 Mar 8.

5.
6.

Monocyte-to-macrophage switch reversibly impaired by Ibrutinib.

Ferrarini I, Rigo A, Montresor A, Laudanna C, Vinante F.

Oncotarget. 2019 Mar 8;10(20):1943-1956. doi: 10.18632/oncotarget.26744. eCollection 2019 Mar 8.

7.

Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia.

Baker SJ, Cosenza SC, Ramana Reddy MV, Premkumar Reddy E.

Oncotarget. 2019 Mar 8;10(20):1932-1942. doi: 10.18632/oncotarget.26735. eCollection 2019 Mar 8.

8.

Relationship between EGFR expression and subcellular localization with cancer development and clinical outcome.

Yan G, Saeed MEM, Foersch S, Schneider J, Roth W, Efferth T.

Oncotarget. 2019 Mar 8;10(20):1918-1931. doi: 10.18632/oncotarget.26727. eCollection 2019 Mar 8.

9.

PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ.

Iwasa M, Harada T, Oda A, Bat-Erdene A, Teramachi J, Tenshin H, Ashtar M, Oura M, Sogabe K, Udaka K, Fujii S, Nakamura S, Miki H, Kagawa K, Ozaki S, Abe M.

Oncotarget. 2019 Mar 8;10(20):1903-1917. doi: 10.18632/oncotarget.26726. eCollection 2019 Mar 8.

10.

Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models.

Kozasa K, Mabuchi S, Matsumoto Y, Kuroda H, Yokoi E, Komura N, Kawano M, Takahashi R, Sasano T, Shimura K, Kodama M, Hashimoto K, Sawada K, Nagasaka K, Kimura T.

Oncotarget. 2019 Mar 8;10(20):1887-1902. doi: 10.18632/oncotarget.26711. eCollection 2019 Mar 8.

11.

ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation.

Khatri A, Gu JJ, McKernan CM, Xu X, Pendergast AM.

Oncotarget. 2019 Mar 8;10(20):1874-1886. doi: 10.18632/oncotarget.26740. eCollection 2019 Mar 8.

12.

Anti-tumor activity of stem cell-derived extracellular vesicles.

Brossa A, Fonsato V, Bussolati B.

Oncotarget. 2019 Mar 8;10(20):1872-1873. doi: 10.18632/oncotarget.26759. eCollection 2019 Mar 8. No abstract available.

13.

Very-high-risk (VHR) localized prostate cancer: an indication for multimodal therapy.

Sundi D, Chapin BF.

Oncotarget. 2019 Mar 8;10(20):1870-1871. doi: 10.18632/oncotarget.26757. eCollection 2019 Mar 8. No abstract available.

14.

Risk stratification for melanoma.

Olsen CM, Whiteman DC.

Oncotarget. 2019 Mar 8;10(20):1868-1869. doi: 10.18632/oncotarget.26755. eCollection 2019 Mar 8. No abstract available.

15.

Assessment of soluble immune mediators as potential biomarkers during immune checkpoint inhibitor therapy.

Matsuo N, Azuma K, Sasada T.

Oncotarget. 2019 Mar 8;10(20):1866-1867. doi: 10.18632/oncotarget.26749. eCollection 2019 Mar 8. No abstract available.

16.

Place of residence and childhood cancer survival.

Delavar A, Johnson KJ.

Oncotarget. 2019 Mar 8;10(20):1864-1865. doi: 10.18632/oncotarget.26717. eCollection 2019 Mar 8. No abstract available.

17.

Neglected players: Tumor associated neutrophils involvement in chronic lymphocytic leukemia progression.

Podaza E, Risnik D.

Oncotarget. 2019 Mar 8;10(20):1862-1863. doi: 10.18632/oncotarget.26716. eCollection 2019 Mar 8. No abstract available.

18.

Harnessing the synergistic potential of biologically targeted therapies in cutaneous T-cell lymphoma.

Patrone CC, Geskin LJ.

Oncotarget. 2019 Mar 8;10(20):1860-1861. doi: 10.18632/oncotarget.26751. eCollection 2019 Mar 8. No abstract available.

19.

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma.

van Herpen CML, Agarwala SS, Hauschild A, Berking C, Beck JT, Schadendorf D, Jansen R, Queirolo P, Ascierto PA, Blank CU, Heinrich MC, Pal RR, Derti A, Antona V, Nauwelaerts H, Zubel A, Dummer R.

Oncotarget. 2019 Mar 5;10(19):1850-1859. doi: 10.18632/oncotarget.26753. eCollection 2019 Mar 5.

20.

An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma.

Givechian KB, Garner C, Benz S, Song B, Rabizadeh S, Soon-Shiong P.

Oncotarget. 2019 Mar 5;10(19):1840-1849. doi: 10.18632/oncotarget.26748. eCollection 2019 Mar 5.

Supplemental Content

Loading ...
Support Center